Terms: = Prostate cancer AND FLT3, STK1, 2322, ENSG00000122025, P36888, FLK2, CD135, RP11-153M24_3 AND Clinical Outcome
423 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
4. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.
Lai C; Wu Z; Li Z; Huang X; Hu Z; Yu H; Yuan Z; Shi J; Hu J; Mulati Y; Liu C; Xu K
Clin Transl Oncol; 2024 May; 26(5):1240-1255. PubMed ID: 38070051
[TBL] [Abstract] [Full Text] [Related]
5. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
6.
de Jong AC; Segbers M; Ling SW; Graven LH; Mehra N; Hamberg P; Brabander T; de Wit R; van der Veldt AAM
J Nucl Med; 2023 Oct; 64(10):1556-1562. PubMed ID: 37536738
[TBL] [Abstract] [Full Text] [Related]
7. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
8. Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.
Le Hars M; Castro-Vega LJ; Rajabi F; Tabatadze D; Romero M; Pinskaya M; Groisman I
Biol Direct; 2023 Jul; 18(1):38. PubMed ID: 37434219
[TBL] [Abstract] [Full Text] [Related]
9. A Multi-institution Study on the Association of Virtual Reality Skills with Continence Recovery after Robot-assisted Radical prostatectomy.
Chu TN; Wong EY; Ma R; Yang CH; Dalieh IS; Hui A; Gomez O; Cen S; Ghazi A; Miles BJ; Lau C; Davis JW; Goldenberg MG; Hung AJ
Eur Urol Focus; 2023 Nov; 9(6):1044-1051. PubMed ID: 37277274
[TBL] [Abstract] [Full Text] [Related]
10. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
[TBL] [Abstract] [Full Text] [Related]
11. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
12. Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study.
Allali S; Loap P; Bibault JE; Krepps S; Deforge A; Moreau D; Durdux C; Giraud P
Prostate; 2023 Jun; 83(8):743-750. PubMed ID: 36911892
[TBL] [Abstract] [Full Text] [Related]
13. Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function.
Román-Fernández A; Mansour MA; Kugeratski FG; Anand J; Sandilands E; Galbraith L; Rakovic K; Freckmann EC; Cumming EM; Park J; Nikolatou K; Lilla S; Shaw R; Strachan D; Mason S; Patel R; McGarry L; Katoch A; Campbell KJ; Nixon C; Miller CJ; Leung HY; Le Quesne J; Norman JC; Zanivan S; Blyth K; Bryant DM
Sci Adv; 2023 Feb; 9(5):eabq1858. PubMed ID: 36735782
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of automated full-body bone metastases delineation methods and their corresponding prognostic power.
Schott B; Weisman AJ; Perk TG; Roth AR; Liu G; Jeraj R
Phys Med Biol; 2023 Jan; 68(3):. PubMed ID: 36580684
[No Abstract] [Full Text] [Related]
15. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
[TBL] [Abstract] [Full Text] [Related]
16. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
17. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
18. Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients.
Majewski W; Lange D; Stanek-Widera A; Itrych B; Krzysztofiak T; Jarząb M; Oczko-Wojciechowska M; Kajor M; Tarnawski R
Pol J Pathol; 2022; 73(1):27-33. PubMed ID: 35848478
[TBL] [Abstract] [Full Text] [Related]
19. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract] [Full Text] [Related]
20. Cranial Radiotherapy for prostate cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.
Schröder C; Windisch P; Lütscher J; Zwahlen DR; Förster R
In Vivo; 2022; 36(4):1841-1846. PubMed ID: 35738629
[TBL] [Abstract] [Full Text] [Related]
[Next]
